Last reviewed · How we verify

HAIC of FOLFOX

Tianjin Medical University Cancer Institute and Hospital · FDA-approved active Small molecule

HAIC of FOLFOX is a Chemotherapy combination (regional delivery) Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently FDA-approved for Hepatocellular carcinoma, Advanced liver cancer. Also known as: Oxaliplatin , fluorouracil, and leucovorin, FOLFOX.

HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration.

HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration. Used for Hepatocellular carcinoma, Advanced liver cancer.

At a glance

Generic nameHAIC of FOLFOX
Also known asOxaliplatin , fluorouracil, and leucovorin, FOLFOX
SponsorTianjin Medical University Cancer Institute and Hospital
Drug classChemotherapy combination (regional delivery)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

HAIC is an interventional oncology technique that infuses chemotherapy agents directly into the hepatic artery supplying the tumor, maximizing local drug exposure while minimizing systemic toxicity. FOLFOX is a combination regimen of 5-fluorouracil, leucovorin, and oxaliplatin that inhibits DNA synthesis and repair. This combination approach leverages regional delivery to enhance efficacy in hepatocellular carcinoma and other liver malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HAIC of FOLFOX

What is HAIC of FOLFOX?

HAIC of FOLFOX is a Chemotherapy combination (regional delivery) drug developed by Tianjin Medical University Cancer Institute and Hospital, indicated for Hepatocellular carcinoma, Advanced liver cancer.

How does HAIC of FOLFOX work?

HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration.

What is HAIC of FOLFOX used for?

HAIC of FOLFOX is indicated for Hepatocellular carcinoma, Advanced liver cancer.

Who makes HAIC of FOLFOX?

HAIC of FOLFOX is developed and marketed by Tianjin Medical University Cancer Institute and Hospital (see full Tianjin Medical University Cancer Institute and Hospital pipeline at /company/tianjin-medical-university-cancer-institute-and-hospital).

Is HAIC of FOLFOX also known as anything else?

HAIC of FOLFOX is also known as Oxaliplatin , fluorouracil, and leucovorin, FOLFOX.

What drug class is HAIC of FOLFOX in?

HAIC of FOLFOX belongs to the Chemotherapy combination (regional delivery) class. See all Chemotherapy combination (regional delivery) drugs at /class/chemotherapy-combination-regional-delivery.

What development phase is HAIC of FOLFOX in?

HAIC of FOLFOX is FDA-approved (marketed).

What are the side effects of HAIC of FOLFOX?

Common side effects of HAIC of FOLFOX include Neutropenia, Thrombocytopenia, Nausea and vomiting, Diarrhea, Peripheral neuropathy, Hepatotoxicity.

Related